Development of novel therapeutics targeting transcription factors for intractable solid tumors and blood cancers
An iterative, precision medicine approach to cancer treatment
Originating from the Chai and Tenen Labs at Harvard Medical School, Believer Pharmaceuticals is a biotech startup targeting transcription factor oncoproteins to advance care for patients with solid tumors and blood cancers.
Our People
Our technology is built upon the cutting edge research of our two PIs, Dr Tenen and Dr Chai from Harvard and National University of Singapore, who are physician scientists with leading expertise in oncoprotein research, in particular, SALL4.
Daniel G Tenen, MD
CO-FOUNDER
World's Leading cancer researcher with >300 high impact publications in oncology
Li Chai, MD
CO-FOUNDER
First report and over 20 years of research in SALL4 in cancers
SCIENCE
Jun Liu, MD PhD
SCIENCE LEAD
Clinical and research expertise in cancer and diagnostics
Bee Hui Liu, PhD
SCIENTIFIC DIRECTOR
Expert in SALL4 biology and drug development
BUSINESS & OPS
Iris Li, MBA
BUSINESS LEAD
Healthcare operating, advising, investment experience
Giovanni Amabile, PhD
SENIOR CONSULTANT
Experienced in bringing lead candidate through IND
Dr. Sridhar Radhakrishnan
Head Medicinal Chem, Cancer Science Institute Singapore
SCIENTIFIC ADVISORY BOARD
Dr. Zhaoling Wang
Medicinal Chem, Ex-Biogen
Dr. Mei Lin Go
Professor of Pharmacology, NUS
Prof. Hagy Nabib
Hepato-billary surgery, Imperial College London
Pipeline
1
BPY
1
2
BDX
BDX
Preclinical
IND
Candidate
Modality
Discovery
Small molecule degrader
Small molecule degrader
Peptide Inhibitor
Small molecule degrader
Peptide Inhibitor
Awards
We Believe in the power of modern medicine
First Look Award
Tough Tech: Most Promising Pharmaceutical Venture
22-23 First Prize
2022 Brace Award Venture Competition
Alnylam Scientific Excellence Award
